Media Articles Related to Exforge (Amlodipine / Valsartan)
Gis map details program aimed at increasing hypertension education using barbershops
Source: Hypertension News From Medical News Today [2014.07.24]
Heart disease and stroke are the second and fourth leading causes of death among black men in the Mississippi Delta region.
Screening for undiagnosed hypertension via electronic health records
Source: Hypertension News From Medical News Today [2014.07.20]
A new study authored by Northwestern Medicine® researchers found that reviewing electronic health records (EHRs) using algorithms can successfully identify patients with previously undiagnosed...
Treatment-resistant hypertension requires proper diagnosis
Source: Hypertension News From Medical News Today [2014.07.09]
High blood pressure - also known as hypertension - is widespread, but treatment often fails. One in five people with hypertension does not respond to therapy.
Hypertension, antihypertension medication and risk of psoriasis
Source: Hypertension News From Medical News Today [2014.07.04]
Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (╬▓)-blocker medication to treat hypertension...
Risk of hypertension increased in pregnancies resulting from egg donation
Source: Fertility News From Medical News Today [2014.07.02]
With an ever-ageing female patient population, egg donation is an increasingly common treatment in infertility.
Published Studies Related to Exforge (Amlodipine / Valsartan)
Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. [2011.09]
Achieving target blood pressure (BP) is influenced by baseline BP. Post hoc analyses of a placebo-controlled trial of amlodipine/valsartan versus monotherapies were conducted to characterize BP control by baseline BP...
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. [2011.07]
Combination therapy may reduce racial/ethnic differences in response to antihypertensives. In this post-hoc analysis, we evaluated treatment response by race/ethnicity among hypertensive adults enrolled in a 12-week, double-blind study in which patients previously uncontrolled (mean sitting systolic blood pressure [MSSBP] >/=150 and <200 mm Hg) on angiotensin receptor blocker (ARB) monotherapy (other than valsartan) for 28 days or more (n = 728) were randomized to amlodipine/valsartan 10/320 mg (intensive) or 5/160 mg (moderate)...
Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. [2011.06]
The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study... All treatments were safe and well tolerated.
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. [2011.04]
OBJECTIVES: Ambulatory blood pressure monitoring (ABPM) has greater predictive value than office blood pressure (BP) with respect to hypertension-related target-organ damage and morbidity. ABPM in a subset of 80 patients from the Exforge Target Achievement trial (N=728) was used to compare the efficacy of intensive-treatment and moderate-treatment regimens of amlodipine/valsartan, and to determine whether treatment differences could be better assessed with ABPM than with office or home BP. Home BP was measured on the morning of clinic visits to minimize differences that timing might have on home versus office BP measures... CONCLUSION: In this first randomized trial evaluating the effects of intensive versus moderate dosing of the combination of amlodipine/valsartan, our data suggest that ABPM was a better method for assessing between-treatment differences than clinic or home BP recordings, although measurement of home BP as a single recording was a limitation of our trial.
Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. [2011.04]
OBJECTIVES: This study compared the effects of morning and evening dosing of amlodipine/valsartan combination on 24-h blood pressure (BP) in patients uncontrolled by amlodipine (5 mg)... CONCLUSION: These results indicate that, in patients with BP uncontrolled by amlodipine (5 mg), morning and evening treatment with amlodipine/valsartan combination have similar effects on circadian BP, especially when 24-h mean values are considered.
Clinical Trials Related to Exforge (Amlodipine / Valsartan)
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily
administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in
patients with essential hypertension.
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension [Completed]
The purpose of this study is to evaluate the safety and efficacy of fixed combination of
valsartan (40 mg and 80 mg) and amlodipine (2. 5 mg and 5 mg), valsartan and amlodipine alone,
and placebo in reducing blood pressure. The study will investigate the dose response
relationship for the combinations, monotherapies and placebo.
Effectiveness of EXforge« and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients [Recruiting]
This study is to demonstrate that valsartan/amlodipine 80/5 mg has superior efficacy
compared with nifedipine 30mg alone in reducing the mean sitting diastolic blood pressure
(MSDBP) and mean sitting systolic blood pressure (MSSBP) from baseline in patients with mild
to moderate hypertension not adequately controlled with monotherapy.
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension. [Completed]
This trial will compare valsartan and amlodipine combination therapies to both valsartan and
amlodipine, and placebo for the treatment of hypertension.
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
The purpose of this study is to determine the effects of treatment with valsartan +
amlodipine to a target systolic blood pressure (SBP)<130 mmHg compared to the Joint National
Commission on the Treatment of Hypertension 7 recommended target SBP of <140 mmHg on the
intrinsic diastolic properties of the myocardium in patients with hypertension and
echocardiographic evidence of diastolic dysfunction.
Reports of Suspected Exforge (Amlodipine / Valsartan) Side Effects
Blood Pressure Increased (85),
Oedema Peripheral (57),
Cerebrovascular Accident (57),
Diabetes Mellitus (44),
Dyspnoea (33), more >>